for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Citius Pharmaceuticals Inc

CTXR.OQ

Latest Trade

0.95USD

Change

0.00(+0.03%)

Volume

45,500

Today's Range

0.90

 - 

0.95

52 Week Range

0.82

 - 

2.52

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.95
Open
0.95
Volume
45,500
3M AVG Volume
2.21
Today's High
0.95
Today's Low
0.90
52 Week High
2.52
52 Week Low
0.82
Shares Out (MIL)
22.08
Market Cap (MIL)
20.97
Forward P/E
-1.56
Dividend (Yield %)
--

Latest Developments

More

Citius Pharmaceuticals To Offer UpTo 8 Mln Units

Citius Announces Change To Primary Endpoint In Mino-Lok Phase 3 Study

Citius Provides Developmental Plans For Mino-Wrap

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.

Industry

Business Services

Contact Info

11 Commerce Dr Fl 1

+1.908.9676677

https://www.citiuspharma.com/

Executive Leadership

Leonard L. Mazur

Executive Chairman of the Board, Secretary

Myron Z. Holubiak

President, Chief Executive Officer, Director

Jaime Bartushak

Chief Financial Officer, Principal Financial Officer

Suren G. Dutia

Director

Eugene Holuka

Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
EPS (USD)

2018

-1.290

2019(E)

-0.610
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.80
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-68.42
Return on Equity (TTM)
-59.79

Latest News

BRIEF-Citius Pharmaceuticals To Sell Up To 1.4 Mln Shares Of Co's Common Stock

* CITIUS PHARMACEUTICALS - TO SELL OR OTHER DISPOSITION FROM TIME TO TIME OF UP TO 1.4 MILLION SHARES OF CO'S COMMON STOCK Source : https://bit.ly/2JdehV7 Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Citius Announces $2 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET Source text for Eikon: Further company coverage:

BRIEF-Citius Reports Progress In Hemorroid Treatment Program

* CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS

BRIEF-Citius Announces $6 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

BRIEF-Citius Pharmaceuticals Says On Nov 27, Board Appointed Jaime Bartushak As CFO And Principal Financial Officer Of Co

* CITIUS PHARMACEUTICALS INC - ON NOV 27, , BOARD APPOINTED JAIME BARTUSHAK AS CFO AND PRINCIPAL FINANCIAL OFFICER OF COMPANY, EFFECTIVE NOV. 27, 2017 Source text: (http://bit.ly/2iwTNyZ) Further company coverage:

BRIEF-Citius Pharmaceuticals files for mixed shelf offering of up to $50 mln - SEC filing

* Citius Pharmaceuticals Inc - files for mixed shelf offering of up to $50 million - SEC filing Source text: (http://bit.ly/2zKcjdY) Further company coverage:

BRIEF-Citius pharmaceuticals receives "fast track" designation by FDA for mino-lok™ investigational trial

* Citius Pharmaceuticals, Inc. Receives "fast track" designation by FDA for mino-lok™ investigational trial Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Citius Pharmaceuticals provides phase 3 update on Mino-Lok clinical trial following FDA meeting

* Citius Pharmaceuticals, Inc provides phase 3 update on Mino-Lok™ clinical trial following FDA meeting

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up